ULTRATAG RBC SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

TECHNETIUM TC 99M RED BLOOD CELLS

متاح من:

CURIUM CANADA INC

ATC رمز:

V09GA06

INN (الاسم الدولي):

TECHNETIUM (99m Tc) STANNOUS AGENT LABELLED CELLS

جرعة:

20MCI

الشكل الصيدلاني:

SOLUTION

تركيب:

TECHNETIUM TC 99M RED BLOOD CELLS 20MCI

طريقة التعاطي:

INTRAVENOUS

الوحدات في الحزمة:

15G/50G

نوع الوصفة الطبية :

Schedule C

المجال العلاجي:

ROENTGENOGRAPHY

ملخص المنتج:

Active ingredient group (AIG) number: 0152627001; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2018-12-07

خصائص المنتج

_ _
_ _
_Page 1 of 18_
PRODUCT MONOGRAPH
ULTRATAG™ RBC
Kit for the Preparation of Technetium Tc 99m-Labeled Red Blood Cells
Solution, 10 to 20 mCi per vial
Radiodiagnostic Agent
Distributed by:
Curium Canada Inc.
2752 boul. Daniel-Johnson, Suite 245-249
Laval, QC, H7T-2R3
CANADA
Date of Revision: May 10, 2019
Control No.: 226012
_ _
_ _
_Page 2 of 18_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
DESCRIPTION....................................................................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................5
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
RADIATION DOSIMETRY
.............................................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................12
SPECIAL HANDLING INSTRUCTIONS
.......................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIEN